Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting 261 enrolled Mabwell (Shanghai) Bioscience Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, Phase I-II, first-in-human (FIH) study of 9MW2921 in patients with locally advanced or metastatic solid tumors refractory to all standard therapies. The objective of this study is to evaluate the safety, tolerability, PK, immunogenicity and Preliminary Antitumor Activity of 9MW2921.

Timeline

Start: 2023-08-28
Primary completion: 2026-09-01
Completion: 2026-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	9MW2921	Unknown	—	Intravenous

Indications

No indication recorded.